Copy
View this email in your browser

'Optimized 5 hydroxy-methyl seq of ctDNA as a biomarker of response in metastatic prostate cancer'

 
Presented by

Dr Felix Feng, Professor of Radiation Oncology, Urology, and Medicine, University of California at San Francisco
 

Dr Feng is a physician-scientist whose research interests include identifying biomarkers of treatment response or resistance in genitourinary cancers and developing rational approaches of targeted treatment for therapy-resistant disease.  Dr. Feng’s laboratory uses high-throughput approaches to interrogate patient samples from clinical trials. His group developed the first clinical-grade biomarker panels that predict prostate cancer response to post-operative radiation (Zhao et al, Lancet Oncology 2016) and androgen deprivation (Zhao et al, JAMA Oncology 2017), and also identified a plasma-based cell-free DNA biomarker that predicts resistance to PARP1 inhibition (Quigley et al, Cancer Discovery 2017).  

Friday 27 August 2021
1pm to 2pm

Register for this seminar
After registering, you will receive a confirmation email containing information about joining the meeting.
Monash Partners Comprehensive Cancer Consortium (MPCCC) is a strategic alliance of health service and research organisations working in partnership to improve cancer outcomes through integrated, collaborative and innovative research, service improvement and clinical care programs. Our partner organisations include Monash University, Hudson Institute of Medical Research, Alfred Health, Monash Health, Peninsula Health, Cabrini Health and Eastern Health.
Twitter
Website
LinkedIn
Copyright © 2021 MPCCC, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp